Patent ID: 11905294
Assignee: BEIGENE, LTD.
Field: Organic fine chemistry (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating a disorder or a disease in a subject, comprising administering to the subject a compound of Formula (I),, , or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,, wherein:
R1 is —NRaRb, wherein Ra and Rb are each independently hydrogen or C1-6alkyl;
R2 is hydrogen, F, Cl, Br, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, —OR12, —SO2R12, —COR12, —CO2R12, —CONR12R13, —C(═NR12)NR13R14, —NR12R13, —NR12COR13, —NR12CONR13R14, —NR12CO2R13, —NR12SONR13R14, —NR12SO2NR13R14, or —NR12SO2R13; wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R11a;
R3 and R4, which may be the same or different, are each independently hydrogen, —C1-6alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R5 and R6, which may be the same or different, are each independently hydrogen, halogen, —C1-6alkyl, —C2-6alkenyl, —C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, —OR12, —SO2R12, —COR12, —CO2R12, —CONR12R13, —C(═NR12)NR13R14, —NR12R13, —NR12COR13, —NR12CONR13R14, —NR12CO2R13, —NR12SONR13R14, —NR12SO2NR13R14, or —NR12SO2R13; wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R11b;
R7, R8 and R10, which may be the same or different, are each independently hydrogen, halogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, —OR12, —SO2R12, —COR12, —CO2R12, —CONR12R13, —C(═NR12)NR13R14, —NR12R13, —NR12COR13, —NR12CONR13R14, —NR12CO2R13, —NR12SONR13R14, —NR12SO2NR13R14, or —NR12SO2R13; wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R11c;
R9 is —CN, —NO2, —OR12, —SO2R12, —SO2NR12R13, —COR12, —CO2R12, —CONR12R13, —C(═NR12)NR13R14, —NR12COR13, —NR12CONR13R14, —NR12CO2R13, —NR12SONR13R14, —NR12SO2NR13R14, or —NR12SO2R13;
R11a, R11b, and R11c, which may be the same or different, are each independently hydrogen, halogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, oxo, —OR12, —SO2R12, —COR12, —CO2R12, —CONR12R13, —C(═NR12)NR13R14, —NR12R13, —NR12COR13, —NR12CONR13R14, —NR12CO2R13, —NR12SONR13R14, —NR12SO2NR13R14, or —NR12SO2R13; and
R12, R13, and R14, which may be the same or different, are each independently hydrogen, —C1-6alkyl, —C2-6 alkenyl, —C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C1-6alkyl, —C2-6alkenyl, —C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with at least one substituent R15;
Alternatively, (R12 and R13), or (R13 and R14), or (R12 and R14), together with the atom(s) to which they are attached, form a 3- to 12-membered saturated, partially or fully unsaturated ring comprising 0, 1 or 2 additional heteroatoms independently selected from —NH, —O—, —S—, —SO— or —SO2—, and said ring is optionally substituted with at least one substituent R15;
R15, at each of its occurrences, is independently hydrogen, halogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —CN, —NO2, oxo, —OR16, —SO2R16, —COR16, —CO2R16, —CONR16R17, —C(═NR16)NR17R18, —NR16R17, —C1-6alkyl-NR16R17, —NR16COR17, —NR16CONR17R18, —NR16CO2R17, —NR16SONR17R18, —NR16SO2NR17R18, or —NR16SO2R17, wherein said C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with halogen, R19, —OR19, —COR19, —SO2R19, or —CO2R19;
wherein each of R16, R17, or R18 is independently hydrogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or
(R16 and R17), or (R16 and R18), or (R17 and R18), together with the atom(s) to which they are attached, form a 3- to 12-membered saturated, partially or fully unsaturated ring comprising 0, 1 or 2 additional heteroatoms independently selected from —NH, —O—, —S—, —SO— or —SO2—, and said ring is optionally substituted with at least one substituent R19, and, wherein R19 is independently hydrogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl, or heteroaryl are each optionally substituted with halogen, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, or haloC2-6alkynyl; and wherein said —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, or haloC2-6alkynyl are each optionally substituted with cycloalkyl, heterocyclyl, aryl, or heteroaryl; and, wherein the disorder or the disease is a B-cell malignancy, pancreatic cancer, breast cancer, lung cancer, melanoma, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or multiple sclerosis (MS).